<DOC>
	<DOC>NCT02155335</DOC>
	<brief_summary>This study is designed to determine whether ulcerative colitis participants prefer delivery of golimumab via a prefilled syringe or the Smartject™ device.</brief_summary>
	<brief_title>Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Antitumor necrosis factor (antiTNF) naive participants with a diagnosis of moderatetosevere ulcerative colitis. Mayo clinic score &gt;= 6, including endoscopic subscore &gt;=2; Previous conventional therapy for a period of at least 3 months with aminosalicylates and at least 3 months with corticosteroids or 6mercaptopurine (6MP) or azathioprine (AZA), unless the participant is intolerant to, or has contraindications to these treatments; AntiTNF experienced participants with an established diagnosis of moderatetosevere ulcerative colitis, either not responding or partially responding to treatment with Remicade (infliximab). The participant must also meet the following criteria prior to initiating firstline antiTNF treatment: Mayo score ≥ 6, including an endoscopic subscore ≥ 2; and previous conventional therapy of at least 3 months with aminosalicylates and at least 3 months with corticosteroids or 6mercaptopurine (6MP) or azathioprine (AZA), unless the participant is intolerant to or have medical contraindications for such therapies (should be documented); Sexually active women of childbearing potential must agree to use a medically accepted method of contraception while receiving study drug and for 6 months after the stop of study drug Has a history of prior selfinjection for any reason; Has concomitant use of other biologic agents; Has active tuberculosis (TB) within 12 months prior to the first injection or has suspected latent TB as indicated by a positive tuberculin skin test. Has an active clinical nontuberculous mycobacterial infection or opportunistic infection within 6 months prior to the first injection; Has had an active infection and/or serious infection within 6 months prior to the first study drug administration; Has had a live viral or bacterial vaccination within 3 months prior to the first study injection or Bacillus CalmetteGuerin vaccination within 12 months prior to the first study drug injection; Has evidence of heart failure of New York Heart Association class 34; Has a history of demyelinating disease such as multiple sclerosis or optic neuritis; Has a history of systemic lupus erythematosus; Has a history of lymphoproliferative disease, or any unknown malignancy or history of malignancy within the prior 5 years, with the exception of nonmelanoma skin cancer that has been treated with no evidence of recurrence; Has had an active hepatitis B infection; Has an allergy or sensitivity to golimumab or its excipients; Is pregnant or breast feeding; Is sensitive to latex.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>